Skip to main content
SpringerLink
Log in

Sarilumab cost effective for active rheumatoid arthritis

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

Reference

  • Fournier M, et al. Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. ClinicoEconomics and Outcomes Research 2019: 117-128, No. 11, 5 Feb 2019. Available from: URL: https://doi.org/10.2147/CEOR.S183076

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarilumab cost effective for active rheumatoid arthritis. PharmacoEcon Outcomes News 822, 29 (2019). https://doi.org/10.1007/s40274-019-5681-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5681-4

Search

Navigation